This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.


Practical considerations

Monitoring patients on Cibinqo1

Laboratory measure

Monitoring guidance

Action

Platelets​​​​​​​

• Before treatment initiation
• 4 weeks after initiation
​​​​​​​• Thereafter according to routine patient management

• Discontinue treatment if platelets are <50 x 103/mm3

Lymphocytes

• Treatment should be interrupted if ALC is <0.5 x 103/mm3 and may be restarted once ALC returns above this value. Treatment should be discontinued if confirmed
​​​​​​​
​​​​​​​• Treatment should be interrupted if ANC is <1 x 103/mm3 and may be restarted once ANC returns above this value

Neutrophils

Haemoglobin

• Treatment should be interrupted if haemoglobin <8 g/dL and may be restarted once haemoglobin returns above this value

Lipids

• Before treatment initiation
• 4 weeks after initiation
​​​​​​​• Thereafter according to clinical guidelines

• Patients should be monitored according to clinical guidelines for hyperlipidaemia

Serious infections
If a patient develops a serious infection, sepsis, or opportunistic infection, consider interruption of Cibinqo until the infection is controlled. Treatment must not be initiated in patients with an active, serious systemic infection.

Vaccines
No data are available on the response to vaccination in patients receiving Cibinqo. Use of live, attenuated vaccines during or immediately prior to Cibinqo therapy is not recommended. It is recommended that patients be brought up to date with all immunisation, including prophylactic herpes zoster vaccinations, in agreement with current immunisation guidelines.

Tuberculosis
Patients should be screened for TB before starting treatment and consider yearly screening for patients in highly endemic areas for TB. Cibinqo must not be given to patients with active TB. For patients with a new diagnosis of latent TB or prior untreated latent TB, preventive therapy for latent TB should be started prior to initiation of Cibinqo.

Viral reactivation
If a patient develops herpes zoster, temporary interruption of treatment should be considered until the episode resolves. Discontinuation or interruption of Cibinqo until the resolution of an eczema herpeticum infection should be considered, depending on the seriousness of the event. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy and during therapy with Cibinqo.​​​​​​​

Elderly
​​​​​​​
Patients 65 years and older were more likely to develop low platelet and ALC values in clinical trials. A higher proportion of patients aged 65 years and older discontinued from clinical studies and were more likely to have serious adverse events compared with younger patients; the incidence rate of herpes zoster in this age group was higher than for younger patients. There are limited data in patients above 75 years of age.

PLEASE SEE CIBINQO SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION​​​​​​​.

Explore more

Dosing

Learn more about flexible dosing in patients on Cibinqo.

Discover oral once-daily dosing

Patient resources

Access resources to help you support your patients on Cibinqo.

View resources

ALC=absolute lymphocyte count; ANC=absolute neutrophil count; TB=tuberculosis.
References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics.
PP-CIB-GBR-0069. October 2021

Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No